Dozens of additional stroke-related genes; potential drug targets identified

The findings reported in Nature also have implications for future dementia care.

Contact: Will Sansom, (210) 567-2579,

SAINT ANTONY (September 28, 2022) – Researchers at the University of Texas Health Sciences Center at San Antonio (UT Health San Antonio) are part of an international team that has discovered 61 additional genetic loci associated with stroke and six genes that are potential targets for therapeutic drugs to prevent or treat stroke. The results, published today (September 28) in Nature, are in 2.5 million people from five different ancestors, more than 200,000 of whom have had a stroke. Members of the GIGASTROKE consortium conducted the research.

Stroke is the second leading cause of death worldwide, responsible for approximately 12% of total deaths and a major contributor to years of life lost or lived with disability. Loci are the physical locations of genes on chromosomes in cells and have been called genetic street addresses.

Sudha Seshadri, MD

Nature The article’s co-author, Sudha Seshadri, MD, professor of neurology at the Joe R. and Teresa Lozano Long School of Medicine at UT Health San Antonio, is the founding director of the Glenn Biggs Institute of the institution for Alzheimer’s disease and neurodegenerative diseases. She leads the Neurology Task Force of CHARGE, an international consortium that has contributed to new findings.

“The population studied in this article has a fairly global representation, including Africa, South Asia, East Asia, Europe and Latin America,” Seshadri said. “Interestingly, one of the groups that remains underrepresented is the American Hispanic population, so there’s still work to be done.”

Stroke is a major risk factor for dementia, and there is significant overlap between the conditions, Seshadri said. Stroke affects small vessels, endothelial cells that line blood vessels, and cells called pericytes that are important for blood vessel formation and other functions. Vascular cognitive impairment and dementia also affect small vessels, endothelial cells and pericytes, Seshadri said.

Photo of Dr. Claudia Satizabal
Claudia Satizabal, PhD

“There is a common biology between stroke and dementia, and there are research methods used in this project to study the genetics of stroke that will make us stronger in the study of dementia,” said research co-author Claudia Satizabal, PhD, assistant professor of population health sciences at UT Health San Antonio and research fellow at the Glenn Biggs Institute.

Co-author Muralidharan Sargurupremraj, PhDwho worked with collaborators in Bordeaux, France, on the global initiative before joining the Glenn Biggs Institute, said the massive project showed the utility of using multiple methods to “pass loci, variations genetics, to the identification of molecules and pathways that may be drug targets for stroke.

Currently known drug targets in Alzheimer’s disease and related dementias have not led to effective therapies so far, Seshadri noted. “I really think I’ll find out novel biology and its research is one of the most promising avenues for finding new drug targets and drugs to treat dementia,” she said.

Over the next 10 years, she said, clinical dementia care, fueled by research such as GIGASTROKE’s findings, “will advance to take a blood sample from a patient and see the genetics of the person, and thus understand what is happening in the brain and do targeted treatment.

The Glenn Biggs Institute, in conjunction with the University of Texas Rio Grande Valley, is an Alzheimer’s disease research center designated by the National Institute on Aging, one of the elite centers for the care and dementia research in the United States.

Stroke genetics informs drug discovery and risk prediction through ancestry

Authors from around the world, including University of Texas Health Sciences Center at San Antonio, Sudha Seshadri, MD; Claudia Satizabal, Ph.D.; and Muralidharan Sargurupremraj, PhD.

First publication: September 28, 2022, Nature

University of Texas Health Sciences Center at San Antonio (UT Health San Antonio), a key driver of San Antonio’s $42.4 billion healthcare and biosciences sector, is South Texas’ largest research university with an annual research portfolio of $350 million. Generating substantial economic impact with its five professional schools, a diverse workforce of over 7,000, an annual operating budget of over $1 billion, and a clinical practice that provides over 2 million patient visits. patients each year, UT Health San Antonio plans to add more than 1,500 higher-paying jobs over the next five years to serve San Antonio, Bexar County, and southern Texas. To learn more about the many ways “We make lives better®”, visit

Stay connected with the University of Texas San Antonio Health Sciences Center on Facebook, Twitter, LinkedIn, instagram and Youtube.

The Glenn Biggs Institute for Alzheimer’s Disease and Neurodegenerative Diseases is dedicated to providing comprehensive care for people with dementia while advancing treatment through clinical trials and research. The Biggs Institute is an Alzheimer’s Disease Research Center (ADRC) designated by the National Institute on Aging (NIA). In addition to patient care and research, the Biggs Institute partners with the School of Nursing at UT Health San Antonio to offer the Caring for the Caregiver program.

Leave a Reply